Delving into the Latest Updates on Shanghai Yunying Medical Technology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Shanghai Yunying Medical Technology Co., Ltd. is committed to creating a new ecosystem for precise cancer diagnosis and treatment. It comprehensively utilizes cutting-edge biotechnologies such as genetic mutation detection, gene methylation detection, and gene editing and recombination to provide an all-round precision medicine solution for cancer, from early precise screening to targeted drug testing and integrated drug development for cancer treatment. Yunying Medical's individualized drug testing technology services cover multiple areas of tumor molecular testing, and its technical service network now covers more than 1,000 hospitals in five major regions of China. Yunying Medical always adheres to the business philosophy of "quality as the foundation, professionalism as the guarantee, and service as the basis," and is efficient, pragmatic, and enterprising, serving the majority of cancer patients with exquisite technical services.

Tags

Neoplasms

Otorhinolaryngologic Diseases

Nervous System Diseases

Oncolytic virus

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5
Endocrinology and Metabolic Disease	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Oncolytic virus	5

Top 5 Target	Count

CD3 x CD86 x PD-1	1

Author: Mei, Lijiang ; Li, Jieyi ; Yu, Zezhong ; Ye, Maosong ; Hu, Qin ; Fu, Huiyu ; Zhang, Xin ; Zhao, Xiaokai ; Liu, Jie ; Wang, Xintao ; Hou, Yingyong ; Qiu, Rumeng ; Xu, Jiahuan ; Liu, Zilong ; Li, Chun ; Deng, Yi ; Wang, Rongping ; Huang, Yuqing ; Huang, Yao ; Yin, Xia ; Zhang, Yong ; Gong, Ziying ; Zhang, Daoyun

Bronchoscopic-assisted discrimination of lung tumors presents challenges, especially in cases with contraindications or inaccessible lesions. Through meta-analysis and validation using the HumanMethylation450 database, this study identified methylation markers for molecular discrimination in lung tumors and designed a sequencing panel. DNA samples from 118 bronchial washing fluid (BWF) specimens underwent enrichment via multiplex PCR before targeted methylation sequencing. The Recursive Feature Elimination Cross-Validation and deep neural network algorithm established the CanDo classification model, which incorporated 11 methylation features (including 8 specific to the TBR1 gene), demonstrating a sensitivity of 98.6% and specificity of 97.8%. In contrast, bronchoscopic rapid on-site evaluation (bronchoscopic-ROSE) had lower sensitivity (87.7%) and specificity (80%). Further validation in 33 individuals confirmed CanDo's discriminatory potential, particularly in challenging cases for bronchoscopic-ROSE due to pathological complexity. CanDo serves as a valuable complement to bronchoscopy for the discriminatory diagnosis and stratified management of lung tumors utilizing BWF specimens.

01 Oct 2023·Cancer research and treatment

Specific Mutations in APC, with Prognostic Implications in Metastatic Colorectal Cancer.

Article

Author: Peng, Huan ; Zang, Jia ; Ying, Jun ; Wang, Xintao ; Gong, Ziying ; Yang, Pengmin ; Li, Jieyi ; Zhang, Daoyun ; Lu, Hao ; Wang, Zhiguo ; Zhao, Xiaokai

PURPOSELoss-of-function mutations in the adenomatous polyposis coli (APC) gene are common in metastatic colorectal cancer (mCRC). However, the characteristic of APC specific mutations in mCRC is poorly understood. Here, we explored the clinical and molecular characteristics of N-terminal and C-terminal side APC mutations in Chinese patients with mCRC.MATERIALS AND METHODSHybrid capture-based next-generation sequencing was performed on tumor tissues from 275 mCRC pati-ents to detect mutations in 639 tumor-associated genes. The prognostic value and gene-pathway difference between APC specific mutations in mCRC patients were analyzed.RESULTSAPC mutations were highly clustered, accounting for 73% of all mCRC patients, and most of them were truncating mutations. The tumor mutation burden of the N-terminal side APC mutations group (n=76) was significantly lower than that of the C-terminal side group (n=123) (p < 0.001), further confirmed by the public database. Survival analysis showed that mCRC patients with N-terminus side APC mutations had longer overall survival than C-terminus side. Tumor gene pathway analysis showed that gene mutations in the RTK/RAS, Wnt and transforming growth factor β signaling pathways of the C-terminal group were significantly higher than those of the N-terminal group (p < 0.05). Additionally, KRAS, AMER1, TGFBR2, and ARID1A driver mutations were more common in patients with C-terminal side APC mutations.CONCLUSIONAPC specific mutations have potential function as mCRC prognostic biomarkers. There are obvious differences in the gene mutation patterns between the C-terminus and N-terminus APC mutations group, which may have certain guiding significance for the subsequent precise treatment of mCRC.

05 Jun 2023·Discover. Oncology

SDH mutations, as potential predictor of chemotherapy prognosis in small cell lung cancer patients.

Article

Author: Sun, Xianwen ; Wang, Xiaofei ; Wen, Wei ; Zhou, Jun ; Liu, Jing ; Yu, Hongjie ; Li, Jieyi ; Gao, Beili ; Zhang, Yuhuan ; Fan, Xiaoyun ; Feng, Xiangran ; Xiang, Yi ; Zhao, XiaoKai ; Dong, Yuchao ; Lv, Mengchen ; Gong, Ziying ; Bao, Zhiyao ; Zhang, Daoyun ; Cheng, Qijian ; Ni, Lei ; Fang, Chen ; Yang, Jin ; Zeng, Ran

PURPOSESmall cell lung cancer (SCLC) is an aggressive and rapidly progressive malignant tumor characterized by a poor prognosis. Chemotherapy remains the primary treatment in clinical practice; however, reliable biomarkers for predicting chemotherapy outcomes are scarce.METHODSIn this study, 78 SCLC patients were stratified into "good" or "poor" prognosis cohorts based on their overall survival (OS) following surgery and chemotherapeutic treatment. Next-generation sequencing was employed to analyze the mutation status of 315 tumorigenesis-associated genes in tumor tissues obtained from the patients. The random forest (RF) method, validated by the support vector machine (SVM), was utilized to identify single nucleotide mutations (SNVs) with predictive power. To verify the prognosis effect of SNVs, samples from the cbioportal database were utilized.RESULTSThe SVM and RF methods confirmed that 20 genes positively contributed to prognosis prediction, displaying an area under the validation curve with a value of 0.89. In the corresponding OS analysis, all patients with SDH, STAT3 and PDCD1LG2 mutations were in the poor prognosis cohort (15/15, 100%). Analysis of public databases further confirms that SDH mutations are significantly associated with worse OS.CONCLUSIONOur results provide a potential stratification of chemotherapy prognosis in SCLC patients, and have certain guiding significance for subsequent precise targeted therapy.

100 Deals associated with Shanghai Yunying Medical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Yunying Medical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

Phase 1 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant oncolytic herpes simplex virus type 1(Shanghai Yunying Medical Technology) ( CD3 x CD86 x PD-1 )	Stomach Cancer More	Phase 1 Clinical
R-4	Neoplasms More	Preclinical
R-146	Neoplasms More	Preclinical
R-149	Neoplasms More	Preclinical
R-153	Neoplasms More	Preclinical